ReviewInternational journal of medical sciences2025
Metabolism and Targeted Therapy of Fibrosis in Chronic Pancreatitis: A Review.
Review in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study.BMC gastroenterology · 2026Article
- Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics.Molecular biomedicine · 2026Review
- Establishment and Comparative Analysis of Four Mouse Models for the Study of Pancreatic Steatosis.International journal of molecular sciences · 2026Article
- The role of glutamine metabolism in the pathogenesis of idiopathic pulmonary fibrosis and its therapeutic potential.Frontiers in oncology · 2026Review
- Metabolomic dysregulation in the association between major depressive disorder and chronic pancreatitis: a large prospective cohort study.Frontiers in nutrition · 2026Article
- Traditional Chinese medicine in pancreatitis: mechanisms, integrative strategies, and clinical perspectives.Frontiers in medicine · 2026Review
- Mast Cells, Pancreatic Stellate Cells, and Telocytes in Chronic Pancreatitis: Ultrastructural Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pancreatitis (CP) is a progressive condition characterized by persistent pancreatic inflammation, tissue destruction, and fibrosis. Recent studies have highlighted the crucial role of metabolic processes in the pathogenesis of pancreatic fibrosis, particularly the metabolic reprogramming of pancreatic stellate cells (PSCs) and immune cells. Disruptions in glucose, lipid, and amino acid metabolism have been shown to play a key role in the progression of CP fibrosis, exacerbating disease severity. Activated PSCs exhibit enhanced glycolysis and lipid metabolism, which promote excessive extracellular matrix (ECM) production and tissue remodeling. Simultaneously, immune cells such as macrophages and T cells undergo metabolic reprogramming, further intensifying inflammation and fibrosis. This review discusses the role of metabolic reprogramming in pancreatic fibrosis and proposes potential therapeutic strategies targeting metabolic pathways, including glycolysis inhibitors, lipid metabolism modulators, and amino acid metabolism regulators. These strategies offer promising prospects for mitigating the progression of CP fibrosis and provide new therapeutic avenues for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.